ketorolac, lidocaine, metoclopramide, midazolam, nitrous oxide Torsades de pointes Hospitalization 15 (10/08/1998) 59, F Droperidol 0.625 mg i.v., cyclobenzaprine 10 mg oral, fluoxetine ...
Concomitant use of ORLYNVAH™ and ketorolac tromethamine is contraindicated ... effects and results of Iterum’s evaluation of strategic alternatives, including the terms, timing, structure ...
Fintel reports that on November 14, 2024, Rodman & Renshaw initiated coverage of Omeros (NasdaqGM:OMER) with a Buy ...
2010). Ketorolac tromethamine is a potent non-selective COX inhibitor that provides significant analgesic effects, especially for moderate to severe postoperative pain. Its strong analgesic properties ...
Concomitant use of ORLYNVAH™ and ketorolac tromethamine is contraindicated ... effects and results of Iterum's evaluation of strategic alternatives, including the terms, timing, structure, value, ...
Medpage Today on MSN24d
FDA Approves Novel Treatment for UTIsThe FDA approved oral sulopenem etzadroxil and probenecid (Orlynvah) to treat uncomplicated urinary tract infections (uUTIs) ...
This extensive, retrospective, payer database analysis evaluated the records of over 17 million patients who had received either ketorolac or Caldolor. Ultimately, 31,046 Caldolor and 124,184 ...
OMIDRIA, Omeros' one approved therapy, has provided boosts to its fraught liquidity over the years. Read why OMER stock is a ...
Pharmaceuticals announced the publication of new real-world outcomes research demonstrating the safety and healthcare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback